Type 2 diabetes–associated variants of the MT 2 melatonin receptor affect distinct modes of signaling
Authors:
- Angeliki KaramitriAKAngeliki Karamitri
- Bianca PlouffeBPBianca Plouffe
- Amélie BonnefondABAmélie Bonnefond
- Jonathan GallionJGJonathan Gallion
- Jean-Luc GuillaumeJGJean-Luc Guillaume
- Alan HegronAHAlan Hegron
- Mathilde BoisselMBMathilde Boissel
- Mickaël CanouilMCMickaël Canouil
- Claudia LangenbergCLClaudia Langenberg
- Nicholas J. WarehamNWNicholas J. Wareham
- Christian Le GouillCGChristian Le Gouill
- 28 August 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (545)
Abstract
Melatonin is produced during the night and regulates sleep and circadian rhythms. Loss-of-function variants in MTNR1B, which encodes the melatonin receptor MT2, a G protein–coupled receptor (GPCR), are associated with an increased risk of type 2 diabetes (T2D). To identify specific T2D-associated signaling pathway(s), we profiled the signaling output of 40 MT2 variants by monitoring spontaneous (ligand-independent) and melatonin-induced activation of multiple signaling effectors. Genetic association analysis showed that defects in the melatonin-induced activation of Gαi1 and Gαz proteins and in spontaneous β-arrestin2 recruitment to MT2 were the most statistically significantly associated with an increased T2D risk. Computational variant impact prediction by in silico evolutionary lineage analysis strongly correlated with the measured phenotypic effect of each variant, providing a predictive tool for future studies on GPCR variants. Together, this large-scale functional study provides an operational framework for the postgenomic analysis of the multiple GPCR variants present in the human population. The association of T2D risk with signaling pathway–specific defects opens avenues for pathway-specific personalized therapeutic intervention and reveals the potential relevance of MT2 function during the day, when melatonin is undetectable, but spontaneous activity of the receptor occurs.Keywords
Funding Information
- Canadian Institutes of Health Research (MOP10501)
- Agence Nationale de la Recherche (ANR-2011-BSV1-012-01 “MLT2D”)
- Agence Nationale de la Recherche (ANR-2011-META “MELA-BETES”)
- Agence Nationale de la Recherche (ANR-12-RPIB-0016 “MED-HET-REC-2”)
- Fondation de la Recherche Médicale (Equipe FRM DEQ20130326503)
- “Who am I?” laboratory of excellence (ANR-11-LABX-0071)
This publication has 70 references indexed in Scilit:
- An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 PeopleScience, 2012
- Melatonin membrane receptors in peripheral tissues: Distribution and functionsMolecular and Cellular Endocrinology, 2012
- A Simple Method for Quantifying Functional Selectivity and Agonist BiasACS Chemical Neuroscience, 2012
- AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndromeJournal of Cellular and Molecular Medicine, 2011
- Circadian Integration of Metabolism and EnergeticsScience, 2010
- A Novel Adaptive Method for the Analysis of Next-Generation Sequencing Data to Detect Complex Trait Associations with Rare Variants Due to Gene Main Effects and InteractionsPLOS Genetics, 2010
- International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin ReceptorsPharmacological Reviews, 2010
- Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetesNature, 2010
- Teaching old receptors new tricks: biasing seven-transmembrane receptorsNature Reviews Drug Discovery, 2010
- Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?British Journal of Pharmacology, 2008